Appeal Court rules that NICE procedure was unfair

BMJ 2008; 336 doi: (Published 08 May 2008) Cite this as: BMJ 2008;336:1035
  1. Clare Dyer
  1. 1BMJ

The hopes of people with mild Alzheimer’s disease of having access to acetylcholinesterase inhibitors through the NHS were boosted last week when three appeal court judges ruled that a key step in the process for appraising the drugs for NHS use was “procedurally unfair.”

The court unanimously overturned a High Court ruling that the National Institute for Health and Clinical Excellence (NICE) acted fairly when it refused to supply the drug company Eisai with a full version of the computer model it used to decide that the treatment would not be cost effective for the early stages of the illness (BMJ 2007;335:319; doi: 10.1136/bmj.39307.630347.DB).

The drugs cost £2.50 (€3.17; …

View Full Text

Log in

Log in through your institution


* For online subscription